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ASCULITIS is inflammation of vessel walls.
It has many causes, although they result in
only a few histologic patterns of vascular in-
flammation. Vessels of any type in any organ can be
affected, a fact that results in a wide variety of signs
and symptoms. These protean clinical manifesta-
tions, combined with the etiologic nonspecificity of
the histologic lesions, complicate the diagnosis of
specific forms of vasculitis. This is problematic be-
cause different vasculitides with indistinguishable
clinical presentations have very different prognoses
and treatments. For example, a patient with purpura,
nephritis, and abdominal pain caused by Henoch–
Schönlein purpura usually has a good prognosis and
needs only supportive care, whereas a patient with
purpura, nephritis, and abdominal pain caused by
microscopic polyangiitis is likely to go on to life-
threatening organ failure if not treated promptly and
appropriately.
In recent years there has been substantial progress
in identifying the attributes of specific types of vas-
culitis that allow accurate diagnosis. One approach
to classifying noninfectious vasculitides categorizes
them, in part, on the basis of the predominant type





is, however, substantial overlap among different vas-
culitides, and the type of vessel involved is merely
one of many features that must be determined be-
fore a diagnosis can be rendered.
This review will focus on noninfectious necrotiz-
ing small-vessel vasculitis, beginning with a history
of the discovery of the major categories of the dis-
ease and concluding with a review of its diagnosis
V
 
and treatment. Small-vessel vasculitis is defined as
vasculitis that affects vessels smaller than arteries,
such as arterioles, venules, and capillaries. Important
categories of the disease are listed in Table 1. It is
important to note that small-vessel vasculitis some-
times, but not always, also affects arteries, and thus
the vascular distribution overlaps with that of the





Two paths of investigation, which eventually inter-
sected, led to our current understanding of small-
vessel vasculitis. One focused on necrotizing arteri-
tis, and the other on purpura.
 
Discovery and Categorization of Necrotizing Arteritis
 
Kussmaul and Maier published the first definitive





 They described a patient with fever, anorexia,
muscle weakness, paresthesias, myalgias, abdominal
pain, and oliguria who was found to have nodular
inflammatory lesions in medium-sized and small ar-
teries throughout the body. They called this condi-
tion periarteritis nodosa, which evolved into the
more pathologically correct name polyarteritis no-
dosa. For more than 50 years (and unfortunately
even today in some settings), any patient with nec-
rotizing arteritis was given a diagnosis of polyarteri-
tis nodosa.
By the 1950s, many investigators had realized that
there were a number of clinically and pathologically
distinct forms of arteritis and that arteritis often oc-
curred as a component of a vasculitis in which many
if not most of the involved vessels were smaller than
arteries (e.g., dermal venules, mucosal arterioles,





 Zeek et al. called this form of vasculitis














 referred to it as the “microscopic form of
periarteritis.” In 1994, the term “microscopic poly-
angiitis” was advocated by an international consen-





will be used in this review. “Microscopic polyangi-
itis” is preferable as a name to “microscopic polyar-
teritis,” because many patients with this type of vas-
culitis have disease confined to arterioles, venules,
and capillaries and thus have no arteritis.
Also by the 1950s, two variants of vasculitis with
associated necrotizing granulomatous inflammation
had been recognized — i.e., Wegener’s granuloma-
tosis and Churg–Strauss syndrome. Wegener’s gran-
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definitive description was provided in 1954 by God-
man and Churg, who identified a triad of features:
systemic necrotizing “angiitis,” necrotizing inflam-





 Subsequently, patients with limit-
ed expressions of the disease were recognized — for





Churg and Strauss, in 1951, described 13 patients
who had asthma, eosinophilia, granulomatous in-





 This disease is now
called Churg–Strauss syndrome.





Churg concluded that Wegener’s granulomatosis,
Churg–Strauss syndrome, and the “microscopic form
of periarteritis” (microscopic polyangiitis) are closely
related and distinct from polyarteritis nodosa. As
 
*Vascular inflammation is categorized as either in-
fectious vasculitis, which is caused by the direct in-
vasion of vessel walls by pathogens (e.g., rickettsial
organisms in Rocky Mountain spotted fever), or
noninfectious vasculitis, which is not caused by the
direct invasion of vessel walls by pathogens (al-
though infections can indirectly induce noninfec-
tious vasculitis — e.g., by generating pathogenic im-





























































Inflammatory bowel disease vasculitis





permission of the publisher. “Large vessel” refers to the aorta and the larg-
est arterial branches directed toward major body regions (e.g., to the ex-
tremities and the head and neck). “Medium-sized vessel” refers to the main
visceral arteries and their branches. “Small vessel” refers to arterioles,
venules, and capillaries, although arteries, especially small arteries, may be
included in this category of vasculitis. Note that all three categories affect
arteries, but only small-vessel vasculitis has a predilection for vessels smaller
than arteries.































































































Giant-cell (temporal) arteritis Granulomatous arteritis of the aorta and 
its major branches, with a predilection 
for the extracranial branches of the ca-
rotid artery. 
 
Often involves the temporal 
artery. Usually occurs in patients more 
than 50 years old and is often associated 
with polymyalgia rheumatica.
 
Takayasu’s arteritis Granulomatous inflammation of the aorta 
and its major branches. 
 
Usually occurs 


















Polyarteritis nodosa Necrotizing inflammation of medium-
sized or small arteries without glomeru-
lonephritis or vasculitis in arterioles, 
capillaries, or venules.
Kawasaki’s disease Arteritis involving large, medium-sized, 
and small arteries and associated with 
mucocutaneous lymph node syndrome. 
 
Coronary arteries are often involved. 
Aorta and veins may be involved. Usual-














Wegener’s granulomatosis† Granulomatous inflammation involving 
the respiratory tract and necrotizing 
vasculitis affecting small-to-medium-
sized vessels (e.g., capillaries, venules, 





Churg–Strauss syndrome† Eosinophil-rich and granulomatous in-
flammation involving the respiratory 
tract and necrotizing vasculitis affecting 
small-to-medium-sized vessels and asso-
ciated with asthma and eosinophilia.
Microscopic polyangiitis† Necrotizing vasculitis with few or no im-
mune deposits affecting small vessels 
(capillaries, venules, or arterioles). 
 
Nec-
rotizing arteritis involving small and 
medium-sized arteries may be present. 
Necrotizing glomerulonephritis is very 
common. Pulmonary capillaritis often 
occurs.
 
Henoch–Schönlein purpura Vasculitis with IgA-dominant immune de-
posits affecting small vessels (capillaries, 
venules, or arterioles). 
 
Typically involves 
skin, gut, and glomeruli and is associated 




Vasculitis with cryoglobulin immune de-
posits affecting small vessels (capillaries, 
venules, or arterioles) and associated 
with cryoglobulins in serum. 
 
Skin and 




Isolated cutaneous leukocytoclastic angii-
tis without systemic vasculitis or glo-
merulonephritis.
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will be discussed later, this conclusion is supported
by recent immunologic observations.
Pathological evaluation of patients with arterial
inflammation demonstrated that histologically indis-
tinguishable necrotizing arteritis (Fig. 2) is shared
by a variety of vasculitides, including polyarteritis
nodosa, Kawasaki’s disease, microscopic polyangiitis,
Wegener’s granulomatosis, and Churg–Strauss syn-
drome. However, whereas medium-sized-vessel vas-
culitis, such as polyarteritis nodosa and Kawasaki’s
disease, involves predominantly if not exclusively ar-
teries, small-vessel vasculitis, such as microscopic
polyangiitis and Wegener’s granulomatosis, may or
may not include arteritis but virtually always affects
vessels smaller than arteries (Fig. 1). By the 1980s,
this concept of “small-vessel vasculitides” that are
distinct from vasculitides affecting predominantly







Historical Description of the Manifestations of Venulitis 
and Capillaritis
 
Purpura (Fig. 3) was the first manifestation of vas-
culitis in vessels smaller than arteries to be extensive-
ly investigated. In 1808, Willan clearly distinguished





 He noted that noninfec-
tious purpura had a predilection for the lower ex-
tremities, was characterized by recurrent groups of
lesions, and could be associated with systemic dis-












 and others elucidated a broad spectrum of
signs and symptoms that were associated with pur-
pura, and thus with small-vessel vasculitis, including
arthritis, peripheral neuropathy, abdominal pain, pul-
monary hemorrhage, epistaxis, iritis, and nephritis.
Osler recognized that these clinical manifestations






In 1919, Goodpasture reported a patient with
pulmonary hemorrhage and rapidly progressive glo-
merulonephritis who had vasculitis affecting small
splenic arteries, arterioles in the gut, pulmonary cap-





nary–renal vasculitic syndrome is now recognized to
be a manifestation of multiple pathogenetically dis-
tinct forms of small-vessel vasculitis. The designation
“Goodpasture’s syndrome” now is usually restricted
to patients with vascular injury caused by antibodies





most patients with pulmonary–renal vasculitic syn-






 Preferred Sites of Vascular Involvement by Selected Vasculitides. 
The widths of the trapezoids indicate the frequencies of involvement of various portions of the vasculature. LCA denotes leukocy-
toclastic angiitis.
Small-Vessel Vasculitis
(e.g., microscopic polyangiitis, Wegener’s granulomatosis)
Medium-Sized-Vessel Vasculitis
(e.g., polyarteritis nodosa, Kawasaki’s disease)
Large-Vessel Vasculitis
(e.g., giant-cell arteritis, Takayasu’s arteritis)
Goodpasture’s syndrome
Isolated cutaneous LCA
Henoch–Schönlein purpura and cryoglobulinemic vasculitis
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and the vasculitis in Goodpasture’s patient was prob-





By the 1950s, the histologic features of necrotiz-
ing vasculitis in venules and other small vessels had
been well described, including the conspicuous leu-
kocytoclasia, which prompted the etiologically non-





 (Fig. 4). The similarity of this pattern of
injury to the Arthus reaction, as well as an associa-
tion between some cases of necrotizing vasculitis
and exposure to drugs and foreign proteins, led to
the contention that some if not most necrotizing





The ability to identify pathogenic antibodies in
tissue and serum by immunofluorescence microsco-
py led to discoveries that allowed the categorization
of certain small-vessel vasculitides — for example,
recognition of antibodies to glomerular basement





; the identification of a
subgroup of patients with purpura, arthralgias, and









 Necrotizing Arteritis in a Small Epineural Artery in a
Nerve-Biopsy Specimen from a Patient with Microscopic Poly-
angiitis.
The muscularis is completely destroyed by fibrinoid necrosis









 Purpura on the Lower Leg of a Patient Found to Have
Leukocytoclastic Angiitis in a Skin-Biopsy Specimen.
There are also several darker areas of necrosis. (Photograph




 Leukocytoclastic Angiitis in a Skin-Biopsy Specimen
from a Patient with Purpura. 
There is extensive karyorrhexis of the vascular and perivascular
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and the detection of pathogen-derived antigens and
cognate antibodies in the vessels of patients with
small-vessel vasculitis that is associated with infections




 These and other observations
supported the concept of an immune-complex patho-
genesis for at least some forms of small-vessel vasculi-
tis; however, evaluation of a wide range of vasculitides
failed to document a high frequency of vascular im-
mune complexes in many important categories, in-
cluding Wegener’s granulomatosis, microscopic poly-





absence or paucity of vascular immune deposits dis-
tinguished the “pauci-immune” vasculitides from the
immune-complex vasculitides, but categorization
based on negative data was unsettling. This problem
was resolved, in part, with the discovery of antineu-




In 1982, Davies and his associates reported hav-
ing detected antibodies that reacted with neutrophil
cytoplasm in eight patients with pauci-immune nec-





 Two years later, Hall et al. confirmed this





 These first two articles on ANCA did not re-
ceive much attention, but a 1985 article by van der
Woude and his collaborators generated substantial
interest by suggesting that detection of ANCA was





 Subsequent studies revealed
that ANCA are closely associated with three major
categories of small-vessel vasculitis: Wegener’s gran-





 — the same three diseases that






ANCA are specific for antigens in neutrophil
granules and monocyte lysosomes. They can be de-
tected with indirect immunofluorescence microsco-
py by using alcohol-fixed neutrophils as substrate.
This produces two major staining patterns: cytoplas-
mic ANCA and perinuclear ANCA. Specific immu-
nochemical assays demonstrate two major antigen










 In patients with vasculitis, approximate-
ly 90 percent of cytoplasmic ANCA are PR3-ANCA
and approximately 90 percent of perinuclear ANCA
are MPO-ANCA. Either ANCA specificity may oc-
cur in a patient with any type of ANCA-associated
small-vessel vasculitis; however, most patients with
Wegener’s granulomatosis have PR3-ANCA (cyto-
plasmic ANCA), whereas most patients with micro-





 It is very im-
portant to realize that approximately 10 percent of
patients with typical Wegener’s granulomatosis or
microscopic polyangiitis have negative assays for
ANCA; thus, ANCA negativity does not completely
rule out these diseases. In addition, the specificity of
ANCA positivity is not absolute; thus, a positive re-
sult is not diagnostic for an ANCA-associated vascu-
litis, especially if the result of an indirect immuno-
fluorescence assay has not been confirmed by a more






The addition of serologic tests for ANCA to the
diagnostic armamentarium provided a positive mark-
er for certain types of pauci-immune small-vessel vas-
culitis. Testing for ANCA, along with other immu-
nopathologic markers such as vascular IgA deposits
and serum cryoglobulins, facilitates the diagnostic
categorization of small-vessel vasculitis (Table 3).
 
DIAGNOSIS AND TREATMENT OF SMALL-
VESSEL VASCULITIS
 
The first step in diagnosis is to recognize that
small-vessel vasculitis is present, and the second,
more difficult step is to determine the specific type
of the disease. The signs and symptoms of small-ves-
sel vasculitis are extremely varied, and many are
shared by all small-vessel vasculitides. Diagnosis re-
quires assessment of both the presence of prerequi-
site features and, just as important, the absence of
incompatible features (Table 3). Accurate diagnosis
is important, because the prognosis and appropriate
treatment are different for different types of small-
vessel vasculitis.
 
General Signs and Symptoms of Small-Vessel Vasculitis
 
Constitutional signs and symptoms, such as fever,
myalgias, arthralgias, and malaise, often accompany
small-vessel vasculitis. Many patients describe a “flu-
like” syndrome early in the course of their disease.
Arthralgias are migratory and affect both small and
large joints, with evidence of synovitis in 10 to 20
percent of patients. Vessels in the skin, respiratory
tract, kidneys, gut, peripheral nerves, and skeletal
muscle are often involved, but the frequencies vary
among categories of small-vessel vasculitis (Table 4).
For example, Wegener’s granulomatosis and micro-
scopic polyangiitis are more likely to cause pulmo-
nary–renal syndrome, whereas cryoglobulinemic vas-
culitis and Henoch–Schönlein purpura are more
likely to cause dermal–renal syndrome.
The most common cutaneous lesion is leukocyto-
clastic angiitis (Fig. 4), which typically causes pur-
pura, sometimes with slight focal necrosis and ulcer-





 Necrotizing arteritis in small dermal and
subcutaneous arteries causes erythematous tender
nodules, focal necrosis, ulceration, and livedo retic-
ularis. Patients with Wegener’s granulomatosis and
Churg–Strauss syndrome may also have cutaneous
Copyright © 1997 Massachusetts Medical Society. All rights reserved. 










nodules caused by granulomatous inflammation.
Urticaria can be a manifestation of small-vessel vas-
culitis, especially when there is immune-complex
deposition with extensive complement activation.
Unlike nonvasculitic allergic urticaria, vasculitic ur-
ticaria lasts for more than a day, may evolve into pur-






Peripheral neuropathy, especially mononeuritis





 This is caused by inflammation of small
epineural arteries and arterioles, resulting in neural
ischemia. Both sensory and motor fibers are in-
volved. Central nervous system disease usually re-
sults from involvement of the meningeal vessel.
Necrotizing inflammation in small arteries, arteri-
oles, and venules in skeletal muscle and viscera caus-
es pain and elevations of tissue enzymes in the
blood. Ischemic ulceration in the gut causes not
only abdominal pain but also blood in the stool. In-
tussusception and perforation of the gut and pancre-
atitis are serious complications.
Respiratory tract disease is frequent in ANCA-
associated small-vessel vasculitis and in Goodpas-
ture’s syndrome but is rare in immune-complex small-
vessel vasculitis, such as Henoch–Schönlein purpura
and cryoglobulinemic vasculitis (Table 4). Inflamma-
tion of the upper respiratory tract is frequent in
small-vessel vasculitis associated with ANCA. Pulmo-
nary manifestations range from fleeting focal infil-
trates to massive pulmonary hemorrhage and he-
moptysis caused by hemorrhagic alveolar capillaritis
(Fig. 5), the most life-threatening feature of small-
vessel vasculitis. Granulomatous pulmonary inflam-
mation of Wegener’s granulomatosis and Churg–
Strauss syndrome cause nodular and occasionally
 
*All of these small-vessel vasculitides can manifest any or all of the shared features of small-vessel
vasculitides, such as purpura, nephritis, abdominal pain, peripheral neuropathy, myalgias, and arthral-
gias. Each is distinguished by the presence and, just as important, the absence of certain specific fea-











































Signs and symptoms of small-vessel 
vasculitis*
" " " " "
IgA-dominant immune deposits " # # # #
Cryoglobulins in blood and vessels # " # # #
ANCA in blood # # " " "
Necrotizing granulomas # # # " "
Asthma and eosinophilia # # # # "
*Approximate frequencies are estimated from data in previous reports.49-65 
TABLE 4. APPROXIMATE FREQUENCY OF ORGAN-SYSTEM MANIFESTATIONS IN SEVERAL 

















Cutaneous 90 90 40 40 60
Renal 50 55 90 80 45
Pulmonary $5 $5 50 90 70
Ear, nose, and throat $5 $5 35 90 50
Musculoskeletal 75 70 60 60 50
Neurologic 10 40 30 50 70
Gastrointestinal 60 30 50 50 50
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cavitating radiographic densities. The acute inflam-
matory and necrotizing pulmonary lesions evolve
into chronic nonspecific sclerotic lesions, such as in-
terstitial fibrosis, organized intraalveolar fibrosis, and
bronchiolitis obliterans.70 
Diagnostic Strategy
There are no agreed-upon diagnostic criteria for
the various categories of small-vessel vasculitis. In
1990 the American College of Rheumatology pub-
lished an approach to classifying vasculitides for clin-
ical trials.71 These criteria were not designed for di-
agnosis, although they are being widely used for this
purpose. They are not adequate for differentiating
among the various clinicopathological expressions of
small-vessel vasculitis. For example, a 20-year-old pa-
tient with small-vessel vasculitis who has purpura, leu-
kocytoclastic angiitis, myalgias, mononeuritis mul-
tiplex, and nephritis would simultaneously fulfill the
College’s criteria for three different categories of vas-
culitis: hypersensitivity vasculitis, Henoch–Schönlein
purpura, and polyarteritis nodosa. The system does
not have a category called “microscopic polyangii-
tis” or “microscopic polyarteritis”; thus, most cases
of ANCA-positive microscopic polyangiitis would be
called hypersensitivity angiitis, according to the Col-
lege’s system.
In 1994 the Chapel Hill International Consensus
Conference proposed names and definitions for se-
lected categories of vasculitis1; however, no diagnos-
tic criteria were suggested. 
The following discussion presents a number of ob-
servations that can be made to help determine which
definition of vasculitis is met in a given patient, and
thus the diagnosis. This requires the knowledgeable
integration of clinical and laboratory data, both pos-
itive and negative. Laboratory assessment for ANCA,
antinuclear antibodies, complement, cryoglobulins,
fecal blood, antibodies to hepatitis B and C, rheu-
matoid factor, azotemia, hematuria, and proteinuria
is useful. Chest and sinus radiographs and computed
tomographic scans may reveal occult respiratory tract
disease. Nerve-conduction studies can document pe-
ripheral neuropathy. Evidence of conditions that are
known to cause vasculitis, such as drug hypersensi-
tivity, infection, rheumatoid arthritis, systemic lupus
erythematosus, cancer, and inflammatory bowel dis-
ease, should be sought. Pathological examination of
involved tissue, such as skin, muscle, nerve, lung, or
kidney, may document small-vessel vasculitis. Immu-
nohistologic evaluation may yield more specific in-
formation, such as the presence of IgA-dominant
vascular immune deposits indicative of Henoch–
Schönlein purpura, or IgM and IgG immune com-
plexes that are consistent with cryoglobulinemic vas-
culitis.
Cutaneous Leukocytoclastic Angiitis
Small-vessel vasculitis may be confined to the skin.
The characteristic acute lesion is leukocytoclastic an-
giitis involving dermal postcapillary venules (Fig. 4).
This lesion is histologically identical to dermal le-
sions occurring as a component of systemic small-
vessel vasculitis.66 Therefore, the onus is on the phy-
sician to rule out systemic disease.
Drug-induced vasculitis should be considered in
any patient with small-vessel vasculitis and will be
substantiated most often in patients with vasculitis
confined to the skin. Drugs cause approximately 10
percent of vasculitic skin lesions.72,73 Drug-induced
vasculitis usually develops within 7 to 21 days after
treatment begins.
Drugs that have been implicated include penicil-
lins, aminopenicillins, sulfonamides, allopurinol, thi-
azides, pyrazolones, retinoids, quinolones, hydanto-
ins, and propylthiouracil.74 Some drugs, such as
penicillins, cause vasculitis by conjugating to serum
proteins and mediating immune-complex vasculitis
that is similar to serum-sickness vasculitis.75 Other
vasculitis-inducing drugs that cause immune-com-
plex formation are foreign proteins, such as streptoki-
nase, cytokines, and monoclonal antibodies.76 In ad-
dition, such drugs as propylthiouracil and hydralazine
appear to cause vasculitis by inducing ANCA,77-80 al-
though a cause-and-effect relation has not been
proved.
Most patients with cutaneous leukocytoclastic an-
giitis have a single episode that resolves spontaneous-
ly within several weeks or a few months.81 Approx-
imately 10 percent will have recurrent disease at
intervals of months to years. In the absence of system-
ic disease, management is usually symptomatic. Drugs
that could cause the disease should be stopped. An-
tihistamines and nonsteroidal antiinflammatory drugs
Figure 5. Pulmonary Hemorrhagic Alveolar Capillaritis in a Pa-
tient with ANCA-Associated Small-Vessel Vasculitis in Whom
Severe Hemoptysis Developed. 
There are numerous neutrophils in the alveolar septa and ex-
tensive hemorrhage into the alveolar spaces. (Hematoxylin and
eosin, !400.)
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help alleviate cutaneous discomfort and reduce asso-
ciated arthralgias and myalgias.81 Severe cutaneous
disease may warrant oral corticosteroid therapy.81 If
signs or symptoms of systemic vasculitis develop,
treatment should be based on the type of systemic
vasculitis the patient has.
Henoch–Schönlein Purpura
Henoch–Schönlein purpura is the most common
systemic vasculitis in children.82 It is characterized by
vascular deposition of IgA-dominant immune com-
plexes,1,33 and preferentially involves venules, capil-
laries, and arterioles (Fig. 1).
Henoch–Schönlein purpura is most frequent in
childhood, with a peak incidence at five years
old.49,50,82 The disease often begins after an upper
respiratory tract infection. Purpura, arthralgias, and
colicky abdominal pain are the most frequent mani-
festations (Table 4). Approximately half the patients
have hematuria and proteinuria, but only 10 to 20
percent have renal insufficiency. Rapidly progressive
renal failure is rare. Pulmonary disease and peripher-
al neuropathy are uncommon.83,84 
The overall prognosis is excellent; thus, supportive
care suffices for most patients. The main long-term
morbidity is from progressive renal disease. End-stage
renal disease develops in approximately 5 percent of
patients.51 Treatment for aggressive Henoch–Schön-
lein purpura glomerulonephritis is controversial.
Corticosteroids, immunosuppressive drugs, and an-
ticoagulant therapy have been tried with contradic-
tory results, but a recent study suggests that com-
bined therapy with corticosteroids and azathioprine
may be beneficial.85 
Although the term “Henoch–Schönlein purpura”
was originally used to designate a syndrome that can
be characterized by many different types of small-
vessel vasculitis (i.e., combinations of purpura, ab-
dominal pain, and nephritis), the use of the term
should now be restricted to the specific clinicopath-
ological entity caused by vascular IgA-dominant im-
mune complexes.1 The misuse of this term for pa-
tients with ANCA-associated small-vessel vasculitis
who present with purpura, abdominal pain, and ne-
phritis is particularly problematic, because these pa-
tients do not have a good prognosis and should be
treated quickly with immunosuppressive therapy, as
will be discussed later in this review.
Cryoglobulinemic Vasculitis
Cryoglobulinemic vasculitis is caused by the local-
ization of mixed cryoglobulins in vessel walls, which
incites acute inflammation. Venules, capillaries, and
arterioles are preferentially involved (Fig. 1).
Patients with this disease have an average age of
approximately 50 years. The most frequent manifes-
tations are purpura, arthralgias, and nephritis (Table
4).52 Mixed cryoglobulins and rheumatoid-factor ac-
tivity are typically detectable in serum. Most patients
have an associated infection with hepatitis C virus,
which is thought to be etiologic.53,86,87 A very dis-
tinctive and diagnostically useful complement ab-
normality is the presence of very low levels of early
components (especially C4) with normal or slightly
low C3 levels.53,87 As with Henoch–Schönlein pur-
pura, the main cause of morbidity is progressive glo-
merulonephritis, which most often has a type I
membranoproliferative phenotype.
Mild disease, such as slight purpura and arthral-
gias, usually is adequately treated with nonsteroidal
antiinflammatory drugs alone. Serious visceral in-
volvement, such as in glomerulonephritis, usually re-
quires treatment with corticosteroids combined with
a cytotoxic drug (e.g., cyclophosphamide), which
improves the outcome of glomerulonephritis and
also ameliorates purpura, arthralgias, and other vas-
culitic symptoms.53,87 Plasmapheresis has been used,
but its value is unproved. Recently, interferon alfa
has been touted as a beneficial adjuvant in patients
with cryoglobulinemic vasculitis associated with hep-
atitis C virus infection,53,87 but larger controlled tri-
als are required before the value of this approach can
be conclusively determined.
ANCA-Associated Small-Vessel Vasculitis
ANCA-associated small-vessel vasculitis is the most
common primary systemic small-vessel vasculitis in
adults and includes three major categories: Wege-
ner’s granulomatosis, microscopic polyangiitis, and
Churg–Strauss syndrome. These histologically iden-
tical small-vessel vasculitides preferentially involve
venules, capillaries, and arterioles, and may also in-
volve arteries and veins (Fig. 1).88 Wegener’s granu-
lomatosis is differentiated from the other two by the
presence of necrotizing granulomatous inflamma-
tion in the absence of asthma; Churg–Strauss syn-
drome is differentiated by the presence of asthma,
eosinophilia, and necrotizing granulomatous inflam-
mation; and microscopic polyangiitis is differentiat-
ed by the absence of granulomatous inflammation
and asthma1 (Tables 2 and 3). Rapid diagnosis of
ANCA-associated small-vessel vasculitis is critically
important, because life-threatening injury to organs
often develops quickly and is mitigated dramatically
by immunosuppressive treatment.
ANCA-associated small-vessel vasculitis affects peo-
ple of all ages but is most common in older adults
in their 50s and 60s, and it affects men and women
equally.54,89 In the United States the disease is more
frequent among whites than blacks.89 Its incidence is
approximately 2 in 100,000 people in the United
Kingdom90 and approximately 1 in 100,000 in Swe-
den.54 Although Wegener’s granulomatosis, micro-
scopic polyangiitis, and Churg–Strauss syndrome are
categorized as ANCA-associated small-vessel vasculi-
tis, it is important to realize that a minority of pa-
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tients with typical clinical and pathological features
of these diseases are ANCA-negative.
Wegener’s granulomatosis. Over 90 percent of
patients with Wegener’s granulomatosis have upper
or lower respiratory tract disease or both.55-57 Mani-
festations of upper respiratory tract disease include
sinus pain, purulent sinus drainage, nasal mucosal
ulceration with epistaxis, and otitis media. More se-
rious complications include necrosis of the nasal
septum with perforation or saddle-nose deformation
and injury to the facial nerve by otitis media result-
ing in facial paralysis. Tracheal inflammation and
sclerosis, often in the subglottic region, cause stridor
and may lead to dangerous airway stenosis, which
occurs in approximately 15 percent of adults and al-
most 50 percent of children with this disease.57 A
minority of patients initially have indolent or aggres-
sive upper respiratory tract disease alone, but most
also have pulmonary disease.
Necrotizing granulomatous pulmonary inflamma-
tion produces nodular radiographic densities, where-
as alveolar capillaritis causes pulmonary hemorrhage
with less fixed and more irregular infiltrates. Massive
pulmonary hemorrhage caused by capillaritis is the
most life-threatening manifestation of ANCA-associ-
ated small-vessel vasculitis and warrants rapid insti-
tution of aggressive immunosuppressive therapy.
Approximately 80 percent of patients with Wege-
ner’s granulomatosis will go on to have glomerulone-
phritis, although less than 20 percent have nephritis
at the time of presentation.57 The glomerulonephri-
tis is characterized by focal necrosis, crescent forma-
tion, and the absence or paucity of immunoglobulin
deposits.35,88 An identical pauci-immune necrotizing
and crescentic glomerulonephritis occurs in patients
with microscopic polyangiitis and Churg–Strauss
syndrome, and also occurs as a disease limited to the
kidneys. Other manifestations of the disease include
ocular inflammation, cutaneous purpura and nod-
ules, peripheral neuropathy, arthritis, and diverse ab-
dominal visceral involvement (Table 4).55-57 
The classic triad of respiratory tract granuloma-
tous inflammation, systemic small-vessel vasculitis,
and necrotizing glomerulonephritis7 readily suggests
the diagnosis, but atypical presentations, such as iso-
lated subglottic stenosis or orbital pseudotumor,
may not. In patients with the latter presentation, a
positive ANCA test is helpful for substantiating a di-
agnosis of Wegener’s granulomatosis.91,92 
Treatment of aggressive Wegener’s granulomatosis,
as well as of microscopic polyangiitis, has three phas-
es: induction of remission, maintenance of remission,
and treatment of relapse.93 After the seminal obser-
vations of Novack and Pearson,94 Fauci and his asso-
ciates documented the value of cyclophosphamide in
the treatment of Wegener’s granulomatosis.55 Cur-
rent induction therapy often uses cyclophosphamide
combined with corticosteroids. Corticosteroids alone
may be adequate for ameliorating indolent limited
disease but are inadequate for patients with general-
ized disease.57 In patients with Wegener’s granuloma-
tosis or microscopic polyangiitis who have aggressive
disease, such as acute nephritis or pulmonary hem-
orrhage, we recommend induction with intravenous
methylprednisolone at a dose of 7 mg per kilogram
of body weight per day for three days, followed by
tapering doses of prednisone. This treatment is com-
bined with oral cyclophosphamide at 2 mg per kilo-
gram per day, or intravenous cyclophosphamide at
0.5 g per square meter of body-surface area per
month, adjusted upward to 1 g per square meter on
the basis of the patient’s leukocyte count.58 Com-
bined therapy with corticosteroids and cyclophos-
phamide induces improvement in over 90 percent of
patients with Wegener’s granulomatosis and com-
plete remission in 75 percent.59 A common strategy
is to discontinue corticosteroids after remission is
achieved, usually within 3 to 5 months, and to con-
tinue cyclophosphamide for 6 to 12 months. An al-
ternative strategy for maintaining remission is con-
version from cyclophosphamide to azathioprine once
remission is achieved.90 Approximately 50 percent of
patients with Wegener’s granulomatosis have at least
one relapse within five years.59 The best treatment
for reversing relapses is controversial but usually in-
volves reinstituting treatment similar to the induc-
tion regimen.57 
Both corticosteroids and cyclophosphamide pre-
dispose patients to life-threatening infections, and
cyclophosphamide causes hemorrhagic cystitis, ovar-
ian and testicular failure, and cancer. For example,
Talar-Williams et al. have estimated the incidence of
bladder cancer after the first exposure to cyclophos-
phamide to be 5 percent 10 years after treatment
and 16 percent after 15 years.95 The risks and bene-
fits of aggressive immunosuppression must be as-
sessed in each patient, and the treatment tailored ac-
cordingly. There should be vigilance for and prompt
treatment of complications arising from treatment.
Less-toxic therapy may be sufficient in patients
with localized or mild Wegener’s granulomatosis. For
example, Sneller et al. achieved remission with low-
dose methotrexate plus prednisone in 71 percent of
patients with Wegener’s granulomatosis that was
“not immediately life-threatening.”96 Methotrexate
also may be useful for maintenance of remission.97
Treatment with methotrexate is limited in patients
with renal disease because of increased toxicity.
Because relapses are associated with respiratory
tract infections and with chronic nasal carriage of
Staphylococcus aureus,98 the antimicrobial agent tri-
methoprim–sulfamethoxazole has been evaluated for
maintenance of remission, with mixed results. Stege-
man et al.99 concluded that it is useful for maintain-
ing remission, but de Groot et al. did not agree.97 
Microscopic polyangiitis. Microscopic polyangiitis
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is characterized by pauci-immune necrotizing small-
vessel vasculitis without clinical or pathological evi-
dence of necrotizing granulomatous inflammation
(Tables 2 and 3).1 Over 80 percent of patients with
microscopic polyangiitis have ANCA, most often
perinuclear ANCA (MPO-ANCA).40-42,54 This helps
distinguish microscopic polyangiitis from ANCA-
negative small-vessel vasculitis but does not distin-
guish microscopic polyangiitis from other types of
disease associated with ANCA. Positive ANCA and
negative serologic tests for hepatitis B help differen-
tiate microscopic polyangiitis from polyarteritis no-
dosa.60 
Pathologically, microscopic polyangiitis may cause
necrotizing arteritis that is histologically identical to
that caused by polyarteritis nodosa. By the approach
advocated by the Chapel Hill Consensus Confer-
ence (Table 2),1 polyarteritis nodosa and microscop-
ic polyangiitis are distinguished pathologically by
the absence of vasculitis in vessels other than arteries
in polyarteritis nodosa and the presence of vasculitis
in vessels smaller than arteries (i.e., arterioles, venules,
and capillaries) in microscopic polyangiitis. Accord-
ing to this definition, the presence of dermal leuko-
cytoclastic venulitis, glomerulonephritis, pulmonary
alveolar capillaritis, or vasculitis in any vessel smaller
than an artery would exclude a diagnosis of polyar-
teritis nodosa and indicate some form of small-vessel
vasculitis. On the other hand, identification of nec-
rotizing arteritis in a skeletal-muscle biopsy or pe-
ripheral-nerve biopsy, for example, indicates some
form of necrotizing vasculitis but is not diagnostic
of polyarteritis nodosa, because many other necro-
tizing vasculitides, such as microscopic polyangiitis,
Wegener’s granulomatosis, and Churg–Strauss syn-
drome, can also affect arteries (Fig. 1).
Microscopic polyangiitis has the same spectrum of
manifestations of small-vessel vasculitis as Wegener’s
granulomatosis but does not include granulomatous
inflammation.54,58,61,62 Approximately 90 percent of
patients have glomerulonephritis, which is accompa-
nied by a variety of other organ involvements (Table
4). Microscopic polyangiitis is the most common
cause of the pulmonary–renal syndrome.22 
Microscopic polyangiitis that is causing major or-
gan damage is treated with a combination of corti-
costeroids and cytotoxic agents. Our treatment ap-
proach is the same as that for aggressive Wegener’s
granulomatosis, which was described earlier in this
review, and uses intravenous methylprednisolone
followed by prednisone combined with intravenous
or oral cyclophosphamide.58 Alveolar capillaritis (Fig.
5) with pulmonary hemorrhage is the most life-threat-
ening complication and should be treated promptly
with combined therapy,58,61 and possibly with plas-
mapheresis.61 The glomerulonephritis is usually rap-
idly progressive if not promptly and appropriately
treated with a combination of high-dose corticoster-
oids and cyclophosphamide, which induces remis-
sion in approximately 80 percent of patients.58,61 The
greatest risk factor for a poor renal outcome is a de-
lay in treatment until renal insufficiency has devel-
oped.63 Relapse occurs in about a third of patients
within two years.54,58,61 Approximately two thirds of
patients who relapse respond to an immunosuppres-
sive regimen similar to the induction therapy.
Because the treatment of microscopic polyangiitis
and Wegener’s granulomatosis is essentially the same
when there is major organ injury, it is not necessary
to distinguish conclusively between these closely re-
lated variants of ANCA-associated small-vessel vas-
culitis before starting treatment. For example, an
ANCA-positive patient with pulmonary infiltrates,
hemoptysis, and pauci-immune crescentic glomeru-
lonephritis on renal biopsy may have either micro-
scopic polyangiitis or Wegener’s granulomatosis. Re-
solving this differential diagnosis should not delay
the start of induction therapy with combined corti-
costeroids and cyclophosphamide.
Churg–Strauss syndrome. Churg–Strauss syn-
drome has three phases: allergic rhinitis and asthma;
eosinophilic infiltrative disease, such as eosinophilic
pneumonia or gastroenteritis; and systemic small-ves-
sel vasculitis with granulomatous inflammation.62,64,65
The vasculitic phase usually develops within three
years of the onset of asthma, although it may be de-
layed for several decades. Approximately 70 percent
of patients with this disease have ANCA, usually
perinuclear ANCA (MPO-ANCA).62 Virtually all pa-
tients have eosinophilia (more than 10 percent eo-
sinophils in the blood).65 
As compared with Wegener’s granulomatosis and
microscopic polyangiitis, Churg–Strauss syndrome
involves much less frequent and less severe renal dis-
ease, but more frequent neuropathy and cardiac dis-
ease.62,65 Coronary arteritis and myocarditis are the
principal causes of morbidity and mortality, account-
ing for approximately 50 percent of deaths, and can
be reduced by early treatment.
High-dose corticosteroid treatment alone is often
adequate, although refractory or relapsing disease
may require the addition of a cytotoxic drug — for
example, in a regimen similar to that used for Wege-
ner’s granulomatosis or microscopic polyangiitis.62,64 
RECOMMENDATIONS
Treatment of a patient with small-vessel vasculitis
should include these steps: recognition that small-
vessel vasculitis is present, determination of as spe-
cific a diagnosis as possible, determination of the
prognosis, and initiation of therapy or referral to an
appropriate specialist. In many patients, small-vessel
vasculitis will have a relatively benign, self-limited
course, especially if disease is limited to the skin;
however, for the patients with aggressive disease,
such as generalized ANCA-associated small-vessel
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vasculitis, it is imperative to begin appropriate treat-
ment quickly. The goal should be neither to over-
treat mild disease nor to undertreat severe disease.
We are indebted to the other members of the Chapel Hill Consen-
sus Conference on the Nomenclature of Systemic Vasculitis for their
contributions to our understanding of vasculitis: K. Andrassy, P.A.
Bacon, J. Churg, W.L. Gross, E.C. Hagen, G.S. Hoffman, G.G.
Hunder, C.G.M. Kallenberg, R.T. McCluskey, R.A. Sinico, A.J.
Rees, L.A. van Es, R. Waldherr, and A. Wiik.
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